Whether regorafenib (Belvango) is a targeted drug and analysis of its mechanism of action

Regorafenib (trade name Stivarga) is an oral small molecule drug that is a targeted anti-cancer drug, but unlike a single-target tyrosine kinase inhibitor, it is a multi-target tyrosine kinase inhibitor (multi-kinase inhibitor). Regorafenib can act on multiple tumor-related signaling pathways simultaneously to inhibit tumor cell growth, angiogenesis, and supporting factors in the tumor microenvironment. Therefore, it is widely used in the treatment of a variety of advanced solid tumors.

The mechanism of action of regorafenib mainly focuses on blocking tumor angiogenesis and tumor cell proliferation signals. It can inhibit receptor kinases such as VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), FGFR (fibroblast growth factor receptor), etc., thereby preventing tumor angiogenesis and weakening the tumor's ability to obtain nutrients and oxygen. At the same time, regorafenib can also inhibit signaling pathways such as RAF, KIT, and RET, directly inhibiting cancer cell proliferation and inducing apoptosis. This multi-target mechanism of action gives it a unique advantage in the treatment of complex tumors.

Compared with traditional chemotherapy drugs, regorafenib does not work by damagingDNA or directly killing rapidly dividing cells, so its toxicity to normal cells is relatively low. Its targeting effect is more selective, allowing patients to maintain a certain quality of life while controlling tumor progression. However, because it acts on multiple targets, some specific side effects may still occur, such as hand and foot rash, fatigue, hypertension, and liver function abnormalities, so regular clinical monitoring and dose adjustment are required.

In general, regorafenib, as a multi-target tyrosine kinase inhibitor, has the characteristics of a targeted drug and can cover multiple key pathways of tumor angiogenesis and tumor cell proliferation. It has shown significant efficacy in the treatment of advanced tumors such as colorectal cancer, gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma. Its multi-target characteristics and good clinical application prospects make regorafenib one of the important representatives in the field of targeted therapy.

Reference materials:https://www.drugs.com/